Abstract
Ideal Induction agent in kidney transplantation has been a subject of debate in the recent times. Ambiguity is more so in the low immunological risk group with uncertain long term benefits and outcomes. We performed a retrospective study and analysed data of kidney transplant recipients who received grafalon & simulect as induction agent from Jan 2011 to Aug 2018, at our centre (ColumbiaAsia Hospital, Hebbal, Bangalore, India)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
